Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory

Autores
Paton, D. J.; Reeve, R.; Capozzo, Alejandra Victoria; Ludi, A.
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.
Instituto de Virología
Fil: Paton, D. J. The Pirbright Institute; Reino Unido
Fil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino Unido
Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ludi, A. The Pirbright Institute; Reino Unido
Fuente
Vaccine 37 (37) : 5515-5524. (3 September 2019)
Materia
Aphthovirus
Virus Fiebre Aftosa
Foot and Mouth Disease
Fiebre Aftosa
Vacuna
Serología
Control de Calidad
Protección
Vaccines
Serology
Quality Controls
Protection
Nivel de accesibilidad
acceso restringido
Condiciones de uso
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/6312

id INTADig_2315911a58e1fbd53ad712fdc436de34
oai_identifier_str oai:localhost:20.500.12123/6312
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratoryPaton, D. J.Reeve, R.Capozzo, Alejandra VictoriaLudi, A.AphthovirusVirus Fiebre AftosaFoot and Mouth DiseaseFiebre AftosaVacunaSerologíaControl de CalidadProtecciónVaccinesSerologyQuality ControlsProtectionFoot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.Instituto de VirologíaFil: Paton, D. J. The Pirbright Institute; Reino UnidoFil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino UnidoFil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ludi, A. The Pirbright Institute; Reino UnidoElsevier2019-11-07T17:43:18Z2019-11-07T17:43:18Z2019-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://www.sciencedirect.com/science/article/pii/S0264410X19310230http://hdl.handle.net/20.500.12123/63120264-410Xhttps://doi.org/10.1016/j.vaccine.2019.07.102Vaccine 37 (37) : 5515-5524. (3 September 2019)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccess2025-09-29T13:44:49Zoai:localhost:20.500.12123/6312instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:44:49.908INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
title Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
spellingShingle Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
Paton, D. J.
Aphthovirus
Virus Fiebre Aftosa
Foot and Mouth Disease
Fiebre Aftosa
Vacuna
Serología
Control de Calidad
Protección
Vaccines
Serology
Quality Controls
Protection
title_short Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
title_full Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
title_fullStr Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
title_full_unstemmed Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
title_sort Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory
dc.creator.none.fl_str_mv Paton, D. J.
Reeve, R.
Capozzo, Alejandra Victoria
Ludi, A.
author Paton, D. J.
author_facet Paton, D. J.
Reeve, R.
Capozzo, Alejandra Victoria
Ludi, A.
author_role author
author2 Reeve, R.
Capozzo, Alejandra Victoria
Ludi, A.
author2_role author
author
author
dc.subject.none.fl_str_mv Aphthovirus
Virus Fiebre Aftosa
Foot and Mouth Disease
Fiebre Aftosa
Vacuna
Serología
Control de Calidad
Protección
Vaccines
Serology
Quality Controls
Protection
topic Aphthovirus
Virus Fiebre Aftosa
Foot and Mouth Disease
Fiebre Aftosa
Vacuna
Serología
Control de Calidad
Protección
Vaccines
Serology
Quality Controls
Protection
dc.description.none.fl_txt_mv Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.
Instituto de Virología
Fil: Paton, D. J. The Pirbright Institute; Reino Unido
Fil: Reeve, R. University of Glasgow. College of Medical, Veterinary and Life Sciences. Institute of Biodiversity, Animal Health and Comparative Medicine; Reino Unido
Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ludi, A. The Pirbright Institute; Reino Unido
description Foot-and-mouth disease (FMD) vaccines must be carefully selected and their application closely monitored to optimise their effectiveness. This review covers serological techniques for FMD vaccine quality control, including potency testing, vaccine matching and post-vaccination monitoring. It also discusses alternative laboratory procedures, such as antigen quantification and nucleotide sequencing, and briefly compares the approaches for FMD with those for measuring protection against influenza virus, where humoral immunity is also important. Serology is widely used to predict the protection afforded by vaccines and has great practical utility but also limitations. Animals differ in their responses to vaccines and in the protective mechanisms that they develop. Antibodies have a variety of properties and tests differ in what they measure. Antibody-virus interactions may vary between virus serotypes and strains and protection may be affected by the vaccination regime and the nature and timing of field virus challenge. Finally, tests employing biological reagents are difficult to standardise, whilst cross-protection data needed for test calibration and validation are scarce. All of this is difficult to reconcile with the desire for simple and universal criteria and thresholds for evaluating vaccines and vaccination responses and means that oversimplification of test procedures and their interpretation can lead to poor predictions. A holistic approach is therefore recommended, considering multiple sources of field, experimental and laboratory data. New antibody avidity and isotype tests seem promising alternatives to evaluate cross-protective, post-vaccination serological responses, taking account of vaccine potency as well as match. After choosing appropriate serological tests or test combinations and cut-offs, results should be interpreted cautiously and in context. Since opportunities for experimental challenge studies of cross-protection are limited and the approaches incompletely reflect real life, more field studies are needed to quantify cross-protection and its correlation to in vitro measurements.
publishDate 2019
dc.date.none.fl_str_mv 2019-11-07T17:43:18Z
2019-11-07T17:43:18Z
2019-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0264410X19310230
http://hdl.handle.net/20.500.12123/6312
0264-410X
https://doi.org/10.1016/j.vaccine.2019.07.102
url https://www.sciencedirect.com/science/article/pii/S0264410X19310230
http://hdl.handle.net/20.500.12123/6312
https://doi.org/10.1016/j.vaccine.2019.07.102
identifier_str_mv 0264-410X
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Vaccine 37 (37) : 5515-5524. (3 September 2019)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619139653566464
score 12.559606